Akums Drugs & Pharma

578.50
-1.95
(-0.34%)
Market Cap
9,105.20 Cr
EPS
22.60
PE Ratio
28.20
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,175.90
52 Week Low
405.00
PB Ratio
2.98
Debt to Equity
0.17
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,676.30
#1 4,02,200.50
35.07
#1 52,041.20
12.06
#1 10,980
-18.99
48.33
6,906.50
1,83,345.90
83.65
9,360.00
0.89
2,117
23.05
68.54
1,513.30
1,22,230.40
23.76
28,409.50
7.12
5,291
30.28
54.26
3,368.00
1,13,988.40
59.12
11,317.00
11.59
2,054
10.91
62.08
1,307.40
1,09,111.80
#1 19.63
33,741.20
12.36
5,725
21.14
54.13
1,001.00
1,00,724.00
21.57
22,573.80
13.82
3,977
-0.19
69.99
2,439.50
1,00,685.20
50.68
12,207.40
19.57
1,925
-10.91
59.65
1,980.90
90,466.80
27.51
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,735.00
73,809.50
52.20
6,409.15
10.80
1,417
27.83
64.97
1,191.30
69,190.90
20.01
31,378.10
17.55
3,366
-0.50
63.70

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
-0.99 %
Net Income Growth
42,875.00 %
Cash Flow Change
-6.64 %
ROE
10,100.00 %
ROCE
5,030.43 %
EBITDA Margin (Avg.)
232.17 %

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
2,078
2,192
3,069
3,267
3,516
4,113
Fixed Assets
645
834
1,021
1,097
1,191
1,397
Current Assets
1,250
1,157
1,864
1,879
1,941
2,275
Capital Work in Progress
57
87
31
103
195
163
Investments
6
19
0
0
0
0
Other Assets
1,371
1,252
2,017
2,066
2,130
2,553
Total Liabilities
2,078
2,192
3,069
3,267
3,516
4,113
Current Liabilities
730
580
1,272
1,266
1,211
894
Non Current Liabilities
627
725
1,172
1,278
1,585
156
Total Equity
721
887
625
723
721
3,064
Reserve & Surplus
721
884
608
689
681
3,016
Share Capital
1
1
14
29
29
31

Cash Flow

Cash Flow
2015
2016
2020
2021
2022
2023
2024
2025
Net Cash Flow
-11
4
71
-70
33
-4
59
-10
Investing Activities
-150
-123
-190
-109
-235
-305
-331
-548
Operating Activities
72
89
28
135
32
177
498
465
Financing Activities
66
37
233
-95
236
125
-108
73

Share Holding

% Holding
Feb 2024
Aug 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
84.91 %
75.26 %
75.26 %
75.26 %
75.26 %
FIIs
0.00 %
5.32 %
7.34 %
6.36 %
5.77 %
DIIs
0.00 %
7.60 %
7.52 %
7.00 %
7.40 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.43 %
2.11 %
3.33 %
3.41 %
Others
15.09 %
7.38 %
7.77 %
8.05 %
8.16 %
No of Share Holders
8
1,38,205
57,531
68,410
69,366

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
18 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Jul 2025 582.05 578.50
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 552.35 582.05
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 570.80 574.50
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Nov 2024 832.70 796.60

Announcements

Resignation Of Senior Management Personnel10 hours ago
Closure of Trading Window9 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication10 days ago
Business Responsibility and Sustainability Reporting (BRSR)Jun 24, 2025
Reg. 34 (1) Annual Report.Jun 24, 2025
Notice Convening 21St Annual General Meeting And Integrated Annual Report Of Financial Year 2024-25Jun 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 18, 2025
The Company Is Hosting Plant Visit For InvestorsJun 16, 2025
Intimation Of Approval Of Revised Notice Of Annual General Meeting (AGM)Jun 07, 2025
Intimation Of Appointment Of Additional Director (Non-Executive- Independent)Jun 04, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2025
Appointment Of SPG & Associates As A Secretarial Auditor Appointment Of Balwinder & Associates As Cost Auditor And Resignation Of Mr. Amrut Medhekar CEO-CDMOMay 26, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 26, 2025
Outcome Of Board MeetingMay 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
Board Meeting Intimation for Consideration And Approval Of Un-Audited (Standalone & Consolidated) Financial Results For The Quarter Ended On 31St March 2025 And Audited (Standalone & Consolidated) Financial Statements For The Year Ended On 31St March 2025May 19, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 17, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Closure of Trading WindowMar 29, 2025
Resignation Of Senior Management PersonnelMar 26, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of PatentFeb 14, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 11, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Statement Of Deviation.Feb 07, 2025
Integrated Filing (Financial)Feb 07, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 07, 2025
Un-Audited Financial Results For The Quarter And Nine Months Ended December 31 2024.Feb 07, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 06Th February 2025Feb 06, 2025
Announcement under Regulation 30 (LODR)-CessationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2025
Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2024.Feb 01, 2025
Update On Income Tax SearchJan 23, 2025
Income Tax SearchJan 22, 2025

Technical Indicators

RSI(14)
Neutral
56.75
ATR(14)
Less Volatile
18.60
STOCH(9,6)
Neutral
76.16
STOCH RSI(14)
Neutral
67.08
MACD(12,26)
Bullish
0.94
ADX(14)
Strong Trend
29.97
UO(9)
Bearish
49.83
ROC(12)
Uptrend And Accelerating
4.44
WillR(14)
Neutral
-28.73

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Nippon India Pharma Fund Direct-Growth
0.57%
520413
0.37%
0.57%
SBI Conservative Hybrid Fund Direct-Growth
0.00%
-377240
-0.20%
-0.23%
Groww Value Fund Direct-Growth
2.14%
20608
2.14%
2.14%
JM Small Cap Fund Direct - Growth
1.03%
-15000
-0.17%
-0.12%
SBI Healthcare Opportunities Fund Direct Plan-Growth
1.24%
-8746
0.09%
0.15%
JM Value Fund Direct Plan-Growth
0.94%
-2899
0.02%
0.07%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.08%
654
0.00%
0.00%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.23%
-539
0.00%
0.03%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.08%
388
0.00%
0.00%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.08%
275
0.00%
0.01%
Axis Nifty 500 Index Fund Direct-Growth
0.01%
220
0.00%
0.00%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.08%
178
0.00%
0.00%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.01%
112
0.00%
0.00%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.08%
80
0.00%
0.00%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.08%
62
0.00%
0.01%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.08%
25
0.00%
0.01%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.08%
24
0.00%
0.00%
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0.02%
9
0.00%
0.00%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.02%
6
0.00%
0.00%
SBI Nifty 500 Index Fund Direct-Growth
0.01%
-4
0.00%
0.00%
ICICI Prudential Nifty 500 Index Fund Direct-Growth
0.01%
3
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct - Growth
0.01%
3
0.00%
0.00%
Mirae Asset Nifty Total Market Index Fund Direct-Growth
0.01%
2
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.12%
1
0.01%
0.02%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.08%
-1
0.00%
0.00%

About Akums Drugs & Pharma

Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and development, regulatory dossier preparation and filing, and testing services. Akums has manufacturing units accredited by global regulatory agencies and specializes in various therapeutic areas. The company has expanded through acquisitions and establishment of new facilities over the years. It operates in three main segments: CDMO, API, and Branded and Generic formulations. Akums has manufactured over 4,000 commercialized formulations across more than 60 dosage forms.
Listing Date
06 Aug, 2024(0 Years, 30 days)